Promising Drug Combo Shrinks Ovarian Tumors and Doubles Treatment Options
A new drug combination of avutometinib and defactinib is showing promising results in treating low-grade serious ovarian cancer, with nearly half of the patients experiencing significant tumor shrinkage. The clinical trial results are particularly significant for younger women who are afflicted with this type of cancer.